NEMLUVIO DIN 02563665
Status: Cancelled Pre Market
Holder: GALDERMA CANADA INC.
Health Canada record
| Active ingredient(s) | NEMOLIZUMAB 30 MG |
|---|
| Dosage form | Powder For Solution |
|---|
| Route | Subcutaneous |
|---|
| Schedule | SCHEDULE D; PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | D11AH12 NEMOLIZUMAB |
|---|
| Original market date | |
|---|
| Current status date | 30-Jul-2026 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Galderma Canada Inc — licence 100073, currently licensed, last inspection rating C (2026-07-07).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing NEMOLIZUMAB
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02563673 | NEMLUVIO | GALDERMA CANADA INC. | Powder For Solution | NEMOLIZUMAB 30 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 36596 | 2025-12-18 | New Drug Submission (NDS) | |
Request a quote for NEMLUVIO
How to read a Canadian DIN record